Bridging the gap in Generalized Pustular Psoriasis (GPP) Bridging the gap in Generalized Pustular Psoriasis (GPP) Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, discusses published insights from GPP patients.
vet scholars symposium vet scholars symposium Veterinary students and researchers from 38 veterinary schools in North America and Europe gathered at the NIH in August to discuss the future of veterinary medicine.
Rare Diseases: Rare but not alone Rare Diseases: Rare but not alone We are committed to listen and learn from patients with rare diseases to deliver breakthrough therapies.
Boehringer Ingelheim Second Transforming Science Day Boehringer Ingelheim Second Transforming Science Day World-renowned top scientists and companies in R&D take the stage at Boehringer Ingelheim’s second Transforming Science Day
Aservo EquiHaler wins Pharmapack Award 2021 Aservo EquiHaler wins Pharmapack Award 2021 Boehringer Ingelheim’s Aservo® EquiHaler® is recognized in the 2021 Pharmapack Awards
Stroke symptoms Stroke symptoms The Angels initiative, stroke symptoms, giving life a chance, optimizing stroke care
Boehringer and ZEISS partnership eye diseases Boehringer and ZEISS partnership eye diseases Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
Distributing medicine globally with pharmaceutical logistics Distributing medicine globally with pharmaceutical logistics From Germany to Australia, here’s what it takes from operations and logistics to ensure patients get their medicine on time, every time.
Production Insights Production Insights Boehringer Ingelheim makes an important contribution to the reliable and sustainable supply of pharmaceuticals
Fast-Track-Designation-NASH Fast-Track-Designation-NASH Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
Combating complex diseases with data Combating complex diseases with data How does big data create disrupting insights for our company? Read about potential use cases and promoting a data mindset
New positive data in Phase III type 2 diabetes trial New positive data in Phase III type 2 diabetes trial DINAMO Phase III trial demonstrated empagliflozin significantly reduced blood sugar levels in children and adolescents with type 2 diabetes
cat feline diabetes medication treatment fda approval cat feline diabetes medication treatment fda approval Boehringer Ingelheim receives FDA approval for SENVELGO®
Boehringer expands production site in Greece Boehringer expands production site in Greece Boehringer expands production site in Greece for new medicine
Boehringer Olaf Scholz break ground for innovation center Boehringer Olaf Scholz break ground for innovation center Boehringer Ingelheim and German Chancellor Olaf Scholz lay the foundation stone for 285 million EUR innovation center
Collaboration Boehringer Ingelheim Veeva technology Collaboration Boehringer Ingelheim Veeva technology Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
Partnership to Develop Urea Cycle Disorders Therapy Partnership to Develop Urea Cycle Disorders Therapy Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Disentangling fibrosis Disentangling fibrosis Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Boehringer Ingelheim 2022 half year results Boehringer Ingelheim 2022 half year results First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Partnership African animal trypanosomiasis Partnership African animal trypanosomiasis New partnership working on solutions to combat African animal trypanosomiasis
Bowel Issues Bowel Issues Find out how to handle changes to bowel habits following cancer treatment from Taking Cancer On Through Flavour
Our Partners_ViraTherapeutics Our Partners_ViraTherapeutics Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.